Bio Preventive Medicine Corp

Capital Structure and Liquidity Bio Preventive Medicine Corp maintains a strong liquidity position with a current ratio of 12.35, indicating significant short-term asset coverage over liabilities. The company holds TWD 250,566,000 in cash and equivalents, which is more than double its total liabilities of TWD 117,943,000. However, the company reported negative operating cash flow of TWD -94,720,000 and free cash flow of TWD -94,567,000, suggesting ongoing operational cash outflows. ### Profitability and Returns The company is currently unprofitable, with a net loss of TWD -99,847,000 and an operating loss of TWD -100,668,000. Return on equity is -32.5%, and return on assets is -23.48%, both significantly below industry norms for medical equipment and diagnostics firms. Gross profit of TWD 2,304,000 is minimal compared to revenue of TWD 2,627,000, indicating high cost pressures or low pricing power. ### Segments and Geographic Exposure The company operates in North America, Europe, Asia, and South America, but disclosed revenue by segment or region is not available. This lack of transparency limits the ability to assess geographic or product concentration risks. The primary product line, in vitro testing reagents, is focused on chronic disease detection, a high-growth but competitive segment. ### Growth Trajectory The company has not provided forward-looking revenue guidance, and historical data shows a net loss in the latest period. Without disclosed revenue growth rates or future projections, it is difficult to assess the company's growth trajectory. The negative operating and free cash flows suggest that the company is not yet generating sufficient cash to sustain operations or fund expansion. ### Risk Factors The company faces liquidity risk due to negative operating cash flow, though its high cash reserves mitigate this risk. There are no immediate dilution risks, as shares outstanding remain unchanged between basic and diluted counts. The negative returns on equity and assets highlight operational inefficiencies or market challenges. No filing-based liquidity or dilution flags were detected. ### Recent Events No recent filings, transcripts, or events were disclosed in the provided data. The company's latest financial snapshot does not include commentary on strategic initiatives, regulatory changes, or market developments that could impact its operations.